Research programme: Parkinson's disease gene therapy - Copernicus Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Copernicus Therapeutics
- Developer Copernicus Therapeutics; University of Kentucky
- Class DNA; Gene therapies
- Mechanism of Action Gene transference; Glial cell line-derived neurotrophic factor expression stimulants; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Parenteral)
- 13 Jan 2009 Preclinical trials in Parkinson's disease in USA (Parenteral)